| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Epstein-Barr virus (EBV) is associated with various neoplastic diseases. The development of new therapy is desired because there is not a specific cure for EBV. The aim of this study is to develop the therapy which induce apoptosis to specific infected cells with EBV episomal vector and Herpesvirus TK-GCV therapy in model mouse of EBV disease.
In this research, at the culture cell level we showed that the inhibitory effect of EBV was enough but the effect was not observed in the mice because decreasing the expression level of TK. However, the new therapy may be developed by increasing the expression level of TK.
|
